Reported results
- Net product revenue for CARDAMYST was $1.0 million for the three months ended September 30, 2026.
- Research and development expense, net of tax credits, was $3.5 million for the three months ended September 30, 2026.
- Selling, general and administrative expense was $24.2 million for the three months ended September 30, 2026.
- Net loss was $25.8 million, or $0.18 per share, for the three months ended September 30, 2026.
- Cash, cash equivalents, and short-term investments totaled $145.4 million as of September 30, 2026.
Guidance
- Company expects cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into late 2028.
- Company expects to reduce operating expenses by approximately 30%.
- Company expects to incur approximately $2 million in one-time charges related to cost-efficiency measures.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
